Creative Biolabs has a mature ferroptosis technology platform, providing customers with a variety of inhibitor/inducer products and services. We will always be committed to the research and development of ferroptosis inducers/inhibitors and products. We have professional ferroptosis discovery technicians and cutting-edge targeting screening facilities, to provide customers with high-quality custom ferroptosis services.
Introduction to Ferroptosis Inducer/Inhibitor
Ferroptosis has become a prominent area of research in the field of cell death over the past decade, with its occurrence primarily attributed to three factors: 1. high levels of polyunsaturated fatty acid side chain phospholipids within the cell. 2. accumulation of iron ions within the cells. 3. inhibition of the cellular antioxidant system. In addition to identifying common ferroptosis characteristics, it is essential to utilize inducers and inhibitors targeting different pathways in the research process. As a result, Creative Biolabs provides development and validation services for ferroptosis inducers and inhibitors to effectively target specific cells (such as cancer cells).
We integrate ferroptosis-inducing drugs with traditional immunotherapy or radiation therapy, from structure, application, model, and target to action characteristics. It not only enhances the bioavailability and targeting of existing inducers/inhibitors but also further broadens the potential of ferroptosis pathways in future cancer immunotherapy.
Ferroptosis inducers
Currently, We mainly provide four ferroptosis inducer development and validation services based on different mechanisms of action. All four inducer types have high specificity for the induction of ferroptosis. Our data have suggested that these inducers do not generally activate markers of other types of cell death during the induction of ferroptosis.
|
Class
|
Ferroptosis Effect
|
MOA
|
Example
|
|
I
|
prevent cystine import, GSH depletion, and loss of GPX4 activity
|
inhibition of XC-cystine uptake
|
Erastin similar
|
|
II
|
covalent interaction with GPX4 and inhibition of enzymes
|
inhibition or degradation of GPX4
|
RSL3, RSL5
|
|
III
|
the depletion of GPX4 and CoQ10
|
consumption of coQ10
|
FIN56
|
|
IV
|
iron oxidation drives lipid peroxidation and GPX4 inactivation
|
induced lipid peroxidation by the overload of iron or polyunsaturated fatty acids (PUFA)
|
FINO2
|
Ferroptosis inhibitors
Nowadays, our ferroptosis inhibitors are designed and developed to target two important features of ferroptosis: ferrous ion overload and lipid peroxide (LPO) accumulation. They act by reducing free iron, eliminating free radicals, and inhibiting lipid peroxidation.
|
Class
|
MOA
|
Example
|
|
iron chelating agent
|
reduce unstable iron in cells and inhibit the Fenton reaction
|
deferoxamine similar
|
|
antioxidants
|
remove ROS and reduce unstable iron in cells
|
ferrostain-1 similar
|
|
lipoxygenase (LOX) inhibitors
|
inhibit 5-LOX
|
AA861 similar
|
|
ACSL4 inhibitor
|
inhibit ACSL4, block the activation of PUFA
|
troglitazone similar
|
|
nitrogen oxides
|
block Fenton reaction and inhibit hydroxyl radical generation
|
TEMPO
|
|
selenium supplement
|
supplement GPX4 abundance and enhance lipid peroxide clearance
|
selenium
|
Cancer Cell Ferroptosis Services
Ferroptosis plays an important regulatory role in tumor occurrence and development and has become a hot spot in the field of tumor mechanism exploration and therapeutic target research. In this case, inducing ferroptosis has been regarded as a promising approach for treating refractory cancers. In Creative Biolabs, we tried to use various drug components to intervene ferroptosis process to induce anti-tumor effects and provide new ideas for anti-tumor therapy. For instance, p53, BECN1, and other molecules have been used to regulate SLC7A11 and GPX4 and induce ferroptosis in various cancer models.
Furthermore, we offer analysis services for studying tumor resistance mediated by genes associated with ferroptosis pathways. In recent projects, our scientists have proven that HSPA5 can bind and stabilize GPX4 under stress to prevent ferroptosis in tumor cells. The resistance of pancreatic cancer cells to gemcitabine products can be reversed by inhibiting the HSPA5-GPX4 pathway. In head and neck tumor models, knocking down or inhibiting SLC7A11 with drugs can enhance the sensitivity of cisplatin to similar product-resistant cell lines to the drug.
Fig.1 GSH/GPX4 Pathway Regulators of Ferroptosis.1
Creative Biolabs is an international CRO company pioneering the development and production of next-generation ferroptosis inhibitors/inducers. Our innovative ferroptosis technology platform and products can provide a powerful tool for the creation of new safe and effective cancer immunotherapy. We can provide many flexible options, from which you can always find a better match for your particular project. If you are interested in our services, please contact us for more details.
Reference
-
Du, Yunxi, and Zhong Guo. "Recent progress in ferroptosis: inducers and inhibitors." Cell death discovery 8.1 (2022): 501.
For Research Use Only | Not For Clinical Use
Download our brochure